Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Dehydroepiandrosterone (DHEA) may help relieve vaginal symptoms in female cancer
survivors.
PURPOSE: This randomized phase III trial studies DHEA to see how well it works compared to
placebo in treating postmenopausal cancer survivors with vaginal symptoms.